Clinical Trials

This trial will consist of three arms: Part A, Part B, and Part C. Part A has two groups. The first group will enroll adult subjects with cystic fibrosis (CF) into a single ascending dose (SAD) treatment group. The second group will enroll adult subjects with CF, including those on background treatment with ORKAMBI® and those not on a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, into a multiple ascending dose (MAD) treatment group. Part B will enroll adult subjects with CF currently on stable ORKAMBI® background therapy for a minimum of 3 months into a Phase II treatment group ...

The goal of the Cystic Fibrosis (CF) Patient Registry, the ongoing data collection effort sponsored by the Cystic Fibrosis Foundation, is to collect data on individuals with Cystic Fibrosis (CF) or individuals with Cystic Fibrosis (CF) related disorders (e.g., CFTR-related metabolic syndrome (CRMS), CFTR-related disorders).

The purpose of this study is to provide evidence of the safety and effectiveness of inhaled mannitol for adult patients with cystic fibrosis.

The purpose of this study is to determine the lowest radiation dose that allows interpretation of chest CT scan.

Our group developed a novel chest CT technology with reduced radiation exposure and procedure duration. This is a new dose optimization and efficiency technology and a tin filter, which greatly reduce the radiation dose compared to a standard chest CT. The procedure is fast and can be performed without sedation.  We therefore aim to validate this promising technology as an alternative clinical monitoring tool against current standard-of-care with CXR. 

This study will explore the effects of delivering a common nebulized drug taken by Cystic fibrosis (CF) patients during exercise.

The study aims to determine if a popular dextrose candy alternative yields a similar glycemic curve compared to the standard oral Dextrose solution used in the Oral Glucose Tolerance Test. Additionally the study aims to determine if substituting the traditional oral dextrose solution used in the Oral Glucose Tolerance Test for a candy alternative yields a higher level of patient satisfaction among children ages 10-21 in the Mayo Clinic Cystic Fibrosis Center. 

The purpose of this study is to describe the prevalence of Mitochondrial DNA mutations associated with aminoglycoside induced ototoxicity (ear toxicity) in Cystic Fibrosis population.

The purpose of the Cystic Fibrosis Patient Registry is to gather and maintain data on all patients with the disease so that current and accurate data can be provided to researchers and clinicians regarding practice patterns, age and gender distributions, clinical outcomes, mortality and morbidity rates, and so that epidemiologic research can be performed.

The purpose of this study is to collect data on individuals with cystic fibrosis (CF) to better understand the illness and ultimately improve the care and survival of those with CF.

The purpose of this study is to obtain breath acoustic recordings and measures of lung mechanics in patients with COPD, asthma, and cystic fibrosis breathing at rest and during light submaximal exercise. The plan is to examine these respiratory acoustics and mechanics in relation to determinants of disease and/or disease states (classic respiratory pathophysiology) and quality of life measures in these patient populations to determine if any relationship or patterns exist when comparing across respiratory diseases and within a condition based on disease severity.       

The purpose of this study is to evaluate the effectiveness of inhaled molgramostim, administered open-label, to adult cystic fibrosis subjects with chronic pulmonary nontuberculous mycobacterial (NTM) infection, with or without ongoing antimycobacterial guideline based combination therapy.

The purpose of this study is to evaluate the effietiveness of remdesivir (RDV) in reducing the rate of of all-cause medically attended visits (MAVs; medical visits attended in person by the participant and a health care professional) or death in non-hospitalized participants with early stage coronavirus disease 2019 (COVID-19) and to evaluate the safety of RDV administered in an outpatient setting.